Hysterosonography (SIS) in India
Get Hysterosonography (SIS) at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Hysterosonography (SIS) in UAE
Hysterosonography (SIS) at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Hysterosonography (Saline Infusion Sonography, or SIS) is a minimally invasive uterine imaging procedure in which sterile saline is instilled into the uterine cavity under real-time transvaginal ultrasound guidance, providing high-resolution delineation of intrauterine pathology such as polyps, submucosal fibroids, adhesions, and congenital anomalies with a diagnostic accuracy exceeding 90% compared to hysteroscopy as the gold standard. International patients travel to India and the UAE for this procedure because both destinations combine JCI- and NABH/DHA-accredited facilities, subspecialty-trained gynaecologic sonologists, and significantly lower out-of-pocket costs than Western healthcare systems. GAF Healthcare coordinates the entire care pathway — from pre-procedure workup and specialist matching to visa facilitation and post-procedure telehealth follow-up — ensuring a seamless, medically rigorous experience for patients arriving from Europe, the Middle East, Africa, and beyond.
Hospital Stay: 0–1 days (outpatient or same-day discharge in virtually all cases) • Total Stay in Country (Fit-to-Fly): 1–3 days (short-haul); 3–5 days (long-haul international flights recommended) • Success Rate: 90–95% diagnostic accuracy versus hysteroscopic confirmation (gold standard)
What Is It?
Hysterosonography — formally termed Saline Infusion Sonography (SIS) or sonohysterography — is a dynamic, office-based uterine evaluation technique that augments conventional transvaginal ultrasound (TVUS) by distending the uterine cavity with 5–20 mL of isotonic sterile saline, creating an acoustic window that transforms the endometrial interface from a single echogenic line into a three-dimensional anatomical map. This acoustic contrast allows the operator to differentiate intracavitary lesions (polyps, pedunculated submucosal fibroids classified under the FIGO leiomyoma subclassification system as Type 0–2) from intramural pathology, and to assess the endometrial lining thickness and contour with a sensitivity of 87–96% and specificity of 91–99% for focal intrauterine lesions — performance metrics that rival diagnostic hysteroscopy while avoiding its procedural risks and costs.
From a physiological standpoint, untreated intrauterine pathology disrupts normal implantation by altering endometrial receptivity, impairing trophoblast invasion, and generating a local pro-inflammatory milieu that is hostile to embryo development. Women with unexplained infertility, recurrent implantation failure in IVF cycles, or abnormal uterine bleeding (AUB) — categorised under the PALM-COEIN classification system endorsed by FIGO — are the primary clinical populations for whom SIS provides clinically actionable anatomical intelligence before proceeding to operative hysteroscopy or assisted reproductive technology (ART).
The current standard of care, as outlined by the American Institute of Ultrasound in Medicine (AIUM), the Royal College of Obstetricians and Gynaecologists (RCOG), and the European Society of Human Reproduction and Embryology (ESHRE), positions SIS as a first-line, office-based triage tool superior to blind endometrial sampling (D&C) and conventional TVUS for intracavitary pathology. In centres of excellence in India and the UAE, SIS is performed using high-frequency (7–12 MHz) transvaginal transducers with 3D/4D volumetric reconstruction capability, and is frequently combined with Doppler flow interrogation (SIS-Doppler or HyCoSy) to simultaneously assess tubal patency — effectively delivering two diagnostic endpoints in a single outpatient session.
Candidates
• IDEAL CANDIDATES (Indications):
• Women with abnormal uterine bleeding (AUB) — heavy menstrual bleeding (HMB), intermenstrual bleeding, or postmenopausal bleeding — where TVUS findings are equivocal or non-diagnostic
• Patients undergoing infertility investigation or repeated IVF implantation failure requiring uterine cavity assessment prior to embryo transfer
• Women with suspected intrauterine adhesions (Asherman syndrome), uterine septum, or Müllerian duct anomalies (classified by the ESHRE/ESGE congenital uterine anomaly system)
• Patients with FIGO Type 0, 1, or 2 submucosal fibroids being evaluated for eligibility for hysteroscopic myomectomy
• Surveillance of endometrial response post-operatively following hysteroscopic polypectomy, metroplasty, or lysis of adhesions
• Women on tamoxifen therapy (breast cancer survivors) requiring periodic endometrial surveillance for hyperplasia or polyp formation
• Patients with a thickened endometrial stripe (>4 mm postmenopausal; >16 mm premenopausal) on routine TVUS who require further characterisation before endometrial biopsy
• REQUIRED PRE-PROCEDURE DIAGNOSTICS:
• Baseline transvaginal ultrasound (TVUS) within 4–6 weeks
• Pelvic examination and cervical inspection to rule out active infection or cervical stenosis
• Endocervical and vaginal swabs (Chlamydia trachomatis, Neisseria gonorrhoeae, bacterial vaginosis screen) — procedure should be deferred if positive
• Complete blood count (CBC), coagulation profile (PT/INR/aPTT) if concurrent biopsy is planned
• Beta-hCG (urine or serum) to exclude pregnancy — procedure is absolutely contraindicated in pregnancy
• Follicle-stimulating hormone (FSH), luteinising hormone (LH), estradiol (E2) in infertility workup
• Previous hysteroscopy or HSG reports, if available, for comparative correlation
• RELATIVE CONTRAINDICATIONS:
• Active pelvic inflammatory disease (PID) or cervicitis — procedure must be deferred until microbiologically confirmed resolution
• Current pregnancy or suspected pregnancy (absolute contraindication)
• Undiagnosed vaginal bleeding at time of procedure
• Severe cervical stenosis precluding catheter placement (requires cervical priming with misoprostol 200–400 mcg vaginally 6–12 hours pre-procedure)
• Recent pelvic surgery within 6 weeks
• Known allergy to ultrasound gel or catheter latex components (hypoallergenic alternatives available)
• SPECIAL CONSIDERATIONS FOR INTERNATIONAL PATIENTS:
• Patients on anticoagulant therapy (warfarin, rivaroxaban, apixaban, dabigatran) should discuss bridging protocols with their treating physician, particularly if simultaneous endometrial biopsy is planned
• Women with a history of LEEP/cone biopsy may require cervical priming
• Diabetic patients and immunosuppressed individuals receive prophylactic antibiotics (doxycycline 100 mg BD for 5 days or azithromycin 500 mg single dose) per ACOG guidelines
Procedure
STANDARD APPROACH — CONVENTIONAL 2D SALINE INFUSION SONOGRAPHY (SIS): The patient is positioned in the dorsal lithotomy position. A speculum examination is performed, the cervix is visualised, and a thin flexible balloon catheter (Ackrad HS or equivalent, 5F) is introduced through the cervical os into the lower uterine segment. The speculum is removed, and a high-frequency transvaginal probe (7–9 MHz) is introduced alongside or following catheter placement. Sterile normal saline (0.9% NaCl, body-temperature warmed to 37°C to minimise cramping) is infused slowly in 1–5 mL aliquots under continuous real-time imaging. The operator systematically surveys the fundus, bilateral cornua, anterior and posterior walls, and the lower uterine segment in both sagittal and coronal planes. Total infusion volume rarely exceeds 20 mL. Total procedure time is 10–20 minutes. Mild-to-moderate cramping is the most common patient experience; prophylactic NSAIDs (ibuprofen 400–600 mg or naproxen sodium 550 mg) administered 30–60 minutes pre-procedure significantly attenuate discomfort.
ADVANCED APPROACH — 3D/4D VOLUMETRIC SONOHYSTEROGRAPHY: Available at tertiary reproductive medicine and gynaecological oncology centres in India and the UAE, 3D SIS employs automated volume sweep technology to acquire a full uterine dataset in a single saline-distended acquisition. The volume dataset is rendered offline using VOCAL (Virtual Organ Computer-aided AnaLysis) software and tomographic ultrasound imaging (TUI) to reconstruct the coronal plane of the uterus — a view physiologically inaccessible to 2D TVUS. This technique has transformed the non-invasive diagnosis of uterine septa (complete vs. partial), arcuate uteri, and bicornuate configurations, replacing diagnostic laparoscopy in many cases. Inversion mode rendering further delineates intracavitary contours. 3D SIS achieves a sensitivity of 97% and specificity of 100% for uterine septum diagnosis in validated studies.
COMBINED SIS + HYSTEROSALPINGO-CONTRAST SONOGRAPHY (HyCoSy/HyFoSy): For infertility patients requiring simultaneous uterine cavity assessment and tubal patency testing, SIS can be combined with HyCoSy (using Echovist/Lumason ultrasound contrast agent) or the newer foam-based HyFoSy technique (ExEm Foam). This one-stop diagnostic approach eliminates the need for a separate HSG or diagnostic laparoscopy in selected patients, reduces radiation exposure, and provides dynamic real-time visualisation of tubal spill under Doppler flow mapping. This approach is particularly recommended in India and the UAE for infertility patients on a time-sensitive IVF preparation timeline.
SIS-GUIDED ENDOMETRIAL BIOPSY (Integrated Sampling): In women with postmenopausal bleeding or at high risk for endometrial hyperplasia/carcinoma (Lynch syndrome carriers, PCOS with prolonged anovulation, tamoxifen users), SIS can be combined with directed endometrial sampling using a Pipelle de Cornier or Tis-u-trap endometrial aspirator under real-time sonographic visualisation, targeting any focal thickening or polypoidal lesion identified during saline infusion. This targeted approach yields superior histological sampling compared to blind Pipelle biopsy, which has a known false-negative rate of 11–15% for focal lesions.
OFFICE HYSTEROSCOPY vs. SIS — DECISION FRAMEWORK: SIS is the preferred first-line tool when the clinical question is 'is there a lesion?' Office hysteroscopy (using 2.9–3.5 mm rigid or semi-rigid scopes, Bettocchi technique, vaginoscopic approach with no speculum or tenaculum) is reserved for cases where biopsy, polypectomy, or targeted therapy is required in the same session. In centres performing SIS and office hysteroscopy in sequence on the same visit ('see-and-treat' protocols), patient journey time and overall costs are further reduced — a model widely adopted in leading gynaecological units in Mumbai, Delhi, Chennai, Dubai, and Abu Dhabi.
Cost of Hysterosonography (SIS): India vs. UAE
Hysterosonography (SIS) is one of the most cost-effective gynaecological diagnostic procedures available, and the price differential between India, the UAE, and Western healthcare markets makes medical travel for this procedure — particularly when bundled with fertility workup or operative hysteroscopy — highly economically rational. In India, SIS is performed at NABH- and JCI-accredited reproductive medicine centres and tertiary hospitals by subspecialty-trained gynaecologic sonologists at a fraction of the cost of equivalent services in the United Kingdom, United States, Australia, or GCC private healthcare systems. In the UAE (Dubai and Abu Dhabi), costs are higher than India but significantly below Western benchmarks, and are accompanied by premium clinical infrastructure, English-Arabic bilingual care teams, and the convenience of visa-on-arrival or visa-free access for over 50 nationalities. The cost ranges below reflect the procedure fee inclusive of the SIS catheter, sterile saline, transvaginal ultrasound session, radiological reporting, and a brief post-procedure consultation. Costs for combined HyCoSy/HyFoSy (tubal patency assessment), 3D volumetric reconstruction, or same-session endometrial biopsy are higher and will be itemised in your personalised GAF Healthcare cost estimate.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $80 – $300 | ~62% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $300 – $700 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-PROCEDURE PREPARATION (Days –14 to –1):
• Remote consultation with GAF Healthcare's partner gynaecologist via secure video platform; review of prior imaging, lab work, and fertility/gynaecological history
• Prescription of prophylactic antibiotics if indicated (doxycycline 100 mg BD for 3–5 days pre-procedure for patients with a history of PID or prior tubal pathology)
• NSAID pre-medication plan confirmed: ibuprofen 600 mg or naproxen 550 mg to be taken 45–60 minutes before the procedure on procedure day
• Optimal timing confirmed: Days 7–10 of the menstrual cycle (immediately post-menstrual), when the endometrium is thin and uniform, maximising contrast between the endometrial lining and infused saline. For postmenopausal women, the procedure can be scheduled on any day.
• Cervical priming with vaginal misoprostol (200–400 mcg) prescribed for 6–12 hours pre-procedure if cervical stenosis is anticipated (nulliparous women, post-menopausal, prior LEEP)
• Travel and accommodation arrangements finalised by GAF Healthcare's logistics team
PHASE 2 — ARRIVAL AND SAME-DAY PROCEDURE:
• Patient arrives at the clinic or hospital 30–45 minutes before the scheduled appointment
• Brief clinical review by the gynaecologist; point-of-care urine beta-hCG confirmation
• Patient voids bladder immediately before the procedure (unlike abdominal ultrasound, a full bladder is not required for transvaginal SIS)
• Patient positioned; speculum inserted; cervix cleansed with povidone-iodine or chlorhexidine solution
• Balloon SIS catheter (5F) inserted; speculum removed; transvaginal probe introduced
• Sterile saline infused under real-time visualisation; systematic survey of uterine cavity completed; representative images and cine loops captured in 2D ± 3D volumetric mode
• Catheter removed; immediate patient comfort assessment performed
• Procedure duration: 10–25 minutes total
• Patient rests in recovery area for 20–30 minutes; mild cramping and light spotting are normal
• Preliminary findings discussed with patient by the gynaecologist immediately post-procedure
• Formal written radiological/gynaecological report issued within 4–24 hours
PHASE 3 — IMMEDIATE POST-PROCEDURE RECOVERY (Day 0–1):
• Mild pelvic cramping typically resolves within 2–6 hours; managed with oral NSAIDs (ibuprofen 400 mg TDS as needed)
• Light watery or blood-tinged vaginal discharge for 24–48 hours is expected and normal
• Patient advised to avoid sexual intercourse, tampons, and swimming for 48–72 hours post-procedure
• Warning signs for which patient should seek urgent review: fever >38°C, severe worsening pelvic pain, heavy vaginal bleeding, or foul-smelling discharge (potential indicators of post-procedural endometritis — incidence <1%)
• Most patients resume normal daily activities, including light office work, within 4–6 hours
PHASE 4 — RESULTS REVIEW AND NEXT-STEP PLANNING (Days 1–3):
• Follow-up teleconsultation with GAF Healthcare's partner gynaecologist to review the formal SIS report and correlate findings with clinical history
• Based on findings, a structured management pathway is outlined:
→ If cavity is normal: proceed to ART/IVF protocol; no operative intervention required
→ If polyp/Type 0–1 fibroid identified: schedule operative hysteroscopy (outpatient or day-case under local or general anaesthesia)
→ If septum/anomaly identified: discussion of metroplasty options and reproductive implications
→ If endometrial hyperplasia suspected: directed biopsy result reviewed; oncology referral pathway initiated if indicated
• Patient fit-to-fly assessment completed; travel clearance issued by treating physician
PHASE 5 — LONG-TERM FOLLOW-UP (Weeks 2–12):
• All post-procedure follow-up and results interpretation provided via GAF Healthcare's telehealth platform — no requirement to return to India or UAE unless operative intervention is planned
• If operative hysteroscopy is recommended, a second trip is coordinated by GAF Healthcare with full pre-operative workup completed remotely
Risks & Considerations
Hysterosonography (SIS) carries a highly favourable safety profile and is classified as a low-risk, minimally invasive diagnostic procedure; serious complications are rare when performed by trained operators following aseptic technique and established patient selection criteria. The most clinically significant risk is post-procedural pelvic infection or endometritis, with an incidence of less than 1% in screened, infection-free patients; this risk is further mitigated by pre-procedure microbiological screening (Chlamydia, gonorrhoea, BV) and prophylactic antibiotic administration (doxycycline or azithromycin) per ACOG and RCOG guidelines. Vasovagal syncope (cervical shock) may occur during or immediately after catheter insertion, particularly in nulliparous or postmenopausal women with cervical stenosis; this is managed by immediate recumbent positioning, IV access if required, and atropine in rare bradycardic cases — all anticipated and managed within the procedure suite. Uterine perforation during catheter placement is exceedingly rare (incidence <0.1%) and virtually confined to cases of severe cervical stenosis or marked uterine anteflexion/retroflexion without pre-procedural cervical priming. Transient pelvic pain and uterine cramping during saline infusion are near-universal, quantified at 3–5/10 on the visual analogue scale on average, and predictably attenuated by pre-procedural NSAIDs. Theoretical risk of air embolism exists if air bubbles are introduced into the saline syringe prior to infusion; this is prevented by careful catheter priming technique. Cervical laceration from tenaculum placement (used in cases of cervical resistance) is a minor but reportable complication, typically self-limiting. False-negative results occur in approximately 4–10% of cases, most commonly when adhesions are tightly apposed or when submucosal fibroids are predominantly intramural (Type 2); in such cases, office hysteroscopy or MRI pelvis with contrast remains the appropriate next diagnostic step. International patients should be counselled that while the procedure itself carries minimal recovery burden, any unexpected need for operative hysteroscopy (identified incidentally during SIS) would require extending their stay by an additional 3–7 days.
Top Hospitals for Hysterosonography (SIS)
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Kings College Hospital Dubai
Dubai, UAE
Aster Hospital Dubai
Dubai, UAE
Top Doctors for Hysterosonography (SIS)
Internationally trained specialists in Gynecology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Tarang Preet Kaur
MBBS, MS, MRCOG, MCh, Fellowship in Urogynaecology, Fellowship in Cosmetic Gynaecology
Urogynaecologist
Max Super Speciality Hospital, Saket, New Delhi, India
11+ Yearsof experience
Dr. Tarang Preet Kaur is a Consultant in Urogynaecology with over 11 years of clinical experience, currently practicing at Max Super Speciality Hospital, Saket in New Delhi. She holds an MCh in Urogynaecology from Edge Hill University, United Kingdom (2024), the MRCOG from the Royal College of Obstetricians & Gynaecologists, and an MS in Obstetrics & Gynaecology from Maulana Azad Medical College, Delhi. Her dual qualification across India and the UK… Read more
Dr. Amrinder Kaur Bajaj
MBBS, MD — Obstetrics & Gynaecology (Gold Medalist), Senior Residency — Obstetrics & Gynaecology, FRSH — Fellow of the Royal Society of Health, FIAMS — Fellow of the Indian Association of Medical Specialists
Obstetrician & Gynaecologist
Fortis Hospital, Gurgaon, Gurgaon, India
42+ Yearsof experience
Dr. Amrinder Kaur Bajaj is one of Delhi-NCR's most experienced gynaecologists, with over four decades spent caring for women at every stage of life. She currently practises as a Consultant in Obstetrics & Gynaecology at Fortis Hospital, Gurgaon, where she brings together deep clinical knowledge and a quietly reassuring bedside manner that patients — and their families — find genuinely comforting. Her academic journey set a high bar early on. She completed… Read more
Dr. Anuradha Khurana
MBBS, DGO (Diploma in Obstetrics & Gynaecology), PG in High Risk Pregnancy and Infertility
Gynecologist & Obstetrics Specialist
Artemis Hospital, New Delhi, India
20+ Yearsof experience
Dr. Anuradha Khurana is a Senior Consultant in Obstetrics and Gynecology at Artemis Hospital, Delhi, with over two decades of hands-on experience in women's health. She is particularly well regarded for her work in high-risk pregnancy management, uterine conditions like fibroids and endometriosis, and complex gynecological surgeries. Patients and families consistently describe her as someone who takes the time to truly listen — and to explain things in a… Read more
Dr. Aswari Kesari Kapoor
MBBS, DGO (Diploma in Gynaecology & Obstetrics), CPS (College of Physicians and Surgeons), DNB (Diplomate of National Board) — Obstetrics & Gynaecology
Obstetrician & Gynecologist
Indraprastha Apollo Hospital, New Delhi, India
23+ Yearsof experience
Dr. Aswari Kesari Kapoor is a seasoned Obstetrician and Gynecologist with over 23 years of hands-on clinical experience. She practices at Indraprastha Apollo Hospital in New Delhi — one of India's most respected multi-specialty institutions. Over the course of her career, she has built a strong reputation for managing complex gynecological conditions alongside high-risk pregnancies, all with a calm and reassuring bedside manner that patients consistently… Read more
Dr. Bindhu K S
MBBS, DNB (Obstetrics & Gynecology), Fellowship in Minimal Access Surgery, FICOG (Fellowship of the Indian College of Obstetricians and Gynaecologists), Certificate in Gynecologic and Obstetric Sonography, Certificate in Appreciation of Well Being in Fetal Heart Disease
Obstetrician & Gynecologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
23+ Yearsof experience
Dr. Bindhu K S is a seasoned Obstetrician and Gynecologist based in Mumbai, currently practicing at Apollo Hospitals, Navi Mumbai. With over two decades of clinical experience, she brings together expertise in both obstetrics and advanced minimally invasive gynecologic surgery. Whether a patient comes with a complex fibroid, troublesome endometriosis, or a high-risk pregnancy, Dr. Bindhu approaches each situation with careful thought and genuine care. Her… Read more
Frequently Asked Questions — Hysterosonography (SIS)
Hysterosonography (SIS) in India at NABH- and JCI-accredited partner hospitals coordinated through GAF Healthcare is estimated at USD $80–$300 for the standard procedure, which includes the SIS balloon catheter, sterile saline, transvaginal ultrasound session with real-time image acquisition, formal radiological/gynaecological reporting, and a brief post-procedure consultation. In the UAE (Dubai and Abu Dhabi) at JCI-accredited, DHA- or DOH-licensed centres, the equivalent procedure is estimated at USD $300–$700, reflecting the higher operational costs of UAE private healthcare and the premium clinical environment. For patients requiring advanced add-ons — 3D volumetric reconstruction, combined HyCoSy/HyFoSy for simultaneous tubal patency assessment, or integrated endometrial biopsy — costs are higher in both destinations and will be itemised in a personalised GAF Healthcare cost estimate. For context, an equivalent SIS procedure in the United Kingdom (private) typically costs GBP £400–£800 (~USD $500–$1,000), in the United States USD $800–$2,000, and in Australia AUD $500–$1,200 — making both India and the UAE economically compelling alternatives, particularly when travel costs are factored into the full comparison. GAF Healthcare provides a transparent, itemised cost estimate inclusive of procedure fees, consumables, reporting, and optional add-ons within 24 hours of receiving a patient's clinical summary.
Hysterosonography (SIS) is performed as a true outpatient procedure — there is no hospital admission, no general anaesthesia in the standard protocol, and no surgical incision. The procedure itself takes 10–25 minutes, followed by a 20–30 minute observation period in the clinic. The vast majority of patients feel sufficiently recovered to leave the facility within 1 hour of the procedure and to return to their hotel or serviced apartment for the remainder of the day. For short-haul international flights (up to 4 hours), GAF Healthcare's clinical partners typically issue fit-to-fly clearance after a minimum of 24–48 hours post-procedure, provided the patient is afebrile, has no abnormal vaginal bleeding beyond mild spotting, and reports pain well controlled on oral NSAIDs. For long-haul international flights (over 4 hours, particularly intercontinental routes from India to Africa, Europe, or the Americas), a minimum of 3–5 days in-country is recommended to allow for results review via formal radiology report (issued within 4–24 hours), a results consultation with the treating gynaecologist to discuss findings and next-step management, and the opportunity to arrange operative hysteroscopy or other indicated procedures if SIS identifies actionable pathology — avoiding the cost and inconvenience of a second medical trip. If SIS is combined with a same-session endometrial biopsy under local anaesthetic, or if the patient experiences any post-procedural complications (endometritis, significant cramping requiring observation), the fit-to-fly timeline is extended to 5–7 days at clinical discretion. GAF Healthcare provides each patient with a formal physician-signed fit-to-fly letter for airline and travel insurance purposes before departure.
The clinical success of Hysterosonography (SIS) is measured primarily by its diagnostic accuracy — its ability to correctly identify or exclude intrauterine pathology when compared to the gold standard of hysteroscopy with or without histological biopsy. Across multiple peer-reviewed meta-analyses and prospective comparative studies, SIS demonstrates a sensitivity of 87–96% and a specificity of 91–99% for the detection of focal intrauterine lesions including endometrial polyps, submucosal fibroids (FIGO Type 0–2), and intrauterine adhesions. For the detection of endometrial polyps specifically, SIS achieves a sensitivity of 93% and specificity of 94% — making it diagnostically equivalent to hysteroscopy for this indication while being significantly less invasive and less costly. The technical success rate — defined as successful catheter placement, adequate saline distension, and completion of the full uterine survey — is 95–98% in unselected patient populations; the 2–5% technical failure rate is almost entirely attributable to cervical stenosis, which is mitigated by pre-procedural cervical priming with vaginal misoprostol. When performed at GAF Healthcare's partner centres by gynaecologists with subspecialty training in reproductive medicine or gynaecological imaging, and using high-frequency transvaginal probes (7–12 MHz) with 3D volumetric capability, diagnostic accuracy reaches the upper bounds of published literature. It is important for patients to understand that SIS is a diagnostic procedure, not a therapeutic one — its 'success' translates into a clear, actionable clinical decision: proceeding to IVF without uterine intervention if the cavity is normal, or scheduling operative hysteroscopy to correct identified pathology before embryo transfer or expectant management. This diagnostic clarity directly improves downstream reproductive and gynaecological outcomes.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides a fully integrated, end-to-end medical travel coordination service that removes every logistical barrier between the international patient and their clinical care, operating across both India and the UAE with equal depth of support infrastructure.
INDIA LOGISTICS: GAF Healthcare's case managers initiate the e-Medical Visa (e-MV) application process on behalf of the patient using India's official online portal. The e-Medical Visa allows three entries within 60 days, is issued within 72 hours for most nationalities, and permits the patient to bring up to two attendants on e-Medical Attendant Visas — a critical provision for patients travelling with a spouse or family member. All hospital invitation letters, treatment cost estimates, and supporting documents required for the visa application are prepared and certified by GAF Healthcare. Partner hospitals are NABH-accredited (National Accreditation Board for Hospitals & Healthcare Providers) and JCI-accredited (Joint Commission International) institutions in Mumbai, Delhi, Bengaluru, Chennai, and Hyderabad — cities served by direct international flights from Europe, the Middle East, Southeast Asia, and Africa.
UAE LOGISTICS (DUBAI & ABU DHABI): Over 50 nationalities enjoy visa-on-arrival or visa-free access to the UAE for 30–90 days, eliminating pre-travel administrative burden for the majority of GAF Healthcare's patient base. For nationalities requiring advance visa arrangements, GAF Healthcare facilitates UAE Tourist Visa or Medical Treatment Visa applications through its UAE-based coordination office, typically resolved within 3–5 working days. Partner hospitals in Dubai hold JCI accreditation and DHA (Dubai Health Authority) licensing; Abu Dhabi partners are DOH (Department of Health Abu Dhabi) licensed and JCI-accredited.
AIRPORT AND GROUND TRANSFERS: Dedicated meet-and-greet service at the international arrival terminal, wheelchair assistance if required, and private air-conditioned vehicle transfers from airport to hotel and between hotel and hospital/clinic on all appointment days are arranged for every GAF Healthcare patient — at no additional coordination fee.
LANGUAGE AND TRANSLATION SUPPORT: GAF Healthcare assigns a dedicated multilingual patient coordinator fluent in the patient's preferred language (Arabic, Russian, French, Swahili, Hindi, Bengali, and others available) who accompanies the patient during the SIS procedure consultation and results discussion, ensuring informed consent is fully understood and no clinical nuance is lost in translation.
ACCOMMODATION FOR PATIENT AND ATTENDANT: GAF Healthcare maintains pre-negotiated rates at partner hotels within 1–3 km of all affiliated hospitals in India and the UAE. Options range from budget-comfortable to five-star luxury. For patients requiring extended stays (e.g., those proceeding to operative hysteroscopy after SIS findings), serviced apartments with kitchenette facilities are arranged to reduce daily living costs. Attendant accommodation within the hospital room is standard in Indian partner hospitals; UAE facilities offer premium adjoining room arrangements.
TELEHEALTH CONTINUITY: All pre-procedure consultations and post-procedure follow-up (results review, next-step planning, prescription renewals) are conducted via GAF Healthcare's HIPAA-compliant telehealth platform, minimising the total number of in-country days required and enabling clinical continuity from the patient's home country.